Rotigotine: High-Affinity Dopamine D2/D3 Receptor Agonist for Parkinson's Disease Research

Executive Summary: Rotigotine is a non-ergoline dopamine agonist demonstrating subnanomolar affinity for D3 (Ki = 0.71 nM) and high affinity for D2 receptors (Ki = 13 nM) (Bhattamisra et al., 2020). It exhibits substantial binding to 5-HT1A and adrenergic α2B receptors, supporting its utility in diverse dopaminergic and serotonergic models (APExBIO). Rotigotine's antiparkinsonian efficacy has been validated in cell-based and animal models, with nose-to-brain delivery enhancing brain bioavailability (Bhattamisra et al., 2020). Its crystalline solid form is soluble in DMSO (≥58 mg/mL) and ethanol (≥25.25 mg/mL), but insoluble in water. APExBIO supplies Rotigotine (SKU A3776) with ≥98% purity for research applications only (APExBIO).

Biological Rationale

Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons, leading to reduced striatal dopamine and symptoms such as tremor, rigidity, and bradykinesia (Bhattamisra et al., 2020). Dopamine agonists like Rotigotine offer a direct method to stimulate dopamine receptors, bypassing endogenous dopamine deficits. Rotigotine's high affinity for D2 and D3 receptors targets key nodes in the nigrostriatal pathway, central to PD pathophysiology. Its additional activity at 5-HT1A and adrenergic α2B receptors may modulate neuropsychiatric and autonomic symptoms often comorbid with PD (APExBIO).

Mechanism of Action of Rotigotine

Rotigotine is a non-ergoline dopamine receptor agonist. Its principal pharmacological action is agonism at dopamine D2 and D3 receptors, with Ki values of 13 nM (D2) and 0.71 nM (D3), measured by radioligand binding assays at pH 7.4 and 25°C (Bhattamisra et al., 2020). The compound’s action at D3 receptors is particularly relevant to limbic and cognitive circuits, while D2 receptor activation underlies its antiparkinsonian effects. Rotigotine also binds to 5-HT1A and adrenergic α2B receptors, expanding its pharmacodynamic profile beyond dopaminergic signaling (APExBIO). Its non-ergoline scaffold minimizes off-target side effects associated with ergoline-based agonists.

Evidence & Benchmarks

• Rotigotine demonstrates Ki = 13 nM for D2 and 0.71 nM for D3 receptors in radioligand binding assays at 25°C, pH 7.4 (Bhattamisra et al., 2020).
• Intranasal delivery of Rotigotine-loaded chitosan nanoparticles enhances brain targeting and bioavailability in rat PD models (Bhattamisra et al., 2020).
• Rotigotine restores tyrosine hydroxylase expression and reduces alpha-synuclein accumulation in SH-SY5Y neuroblastoma cells exposed to 6-OHDA (Bhattamisra et al., 2020).
• Behavioral reversal of haloperidol-induced catalepsy and akinesia is observed following Rotigotine administration in vivo (Bhattamisra et al., 2020).
• Rotigotine is supplied by APExBIO (SKU A3776) at ≥98% purity, as a crystalline solid, soluble in DMSO (≥58 mg/mL) and ethanol (≥25.25 mg/mL), but insoluble in water (APExBIO).

Applications, Limits & Misconceptions

Rotigotine serves as a dopamine receptor agonist for Parkinson's disease research and dopaminergic signaling studies. It is validated for use in cell-based assays, animal models, and bioavailability studies. Its affinity for 5-HT1A and α2B adrenergic receptors allows for research into serotonergic and adrenergic modulation. Rotigotine is not intended for diagnostic or therapeutic use in humans (APExBIO).

Common Pitfalls or Misconceptions

• Not water-soluble: Rotigotine is insoluble in water; use DMSO or ethanol for dissolution (APExBIO).
• Research use only: Not for clinical, diagnostic, or therapeutic applications (APExBIO).
• Stability: Solutions are unstable long-term; use promptly after preparation (APExBIO).
• First-pass metabolism: Oral bioavailability is low due to hepatic metabolism (Bhattamisra et al., 2020).
• Off-target activity: Although selective, Rotigotine also binds 5-HT1A and α2B receptors, which may confound strict dopaminergic pathway studies (APExBIO).

Workflow Integration & Parameters

Rotigotine is supplied as a crystalline solid by APExBIO, SKU A3776, with ≥98% purity. For cell-based assays, dissolve in DMSO (≥58 mg/mL) or ethanol (≥25.25 mg/mL). Store solid at -20°C; avoid long-term solution storage. Use freshly prepared solutions for reproducible results. The compound is suitable for in vitro dopamine receptor activation, neuroprotection assays, and in vivo PD model studies. For advanced guidance on integrating Rotigotine into dopaminergic signaling pathway research, see this detailed analytical review, which expands on workflow parameters and stability considerations not covered here. For a strategic comparison of Rotigotine’s mechanistic profile, this mechanistic insight article offers a translational perspective; this dossier provides updated benchmarks and experimental boundaries.

Conclusion & Outlook

Rotigotine is a validated dopamine D2/D3 receptor agonist with robust evidence supporting its use in antiparkinsonian activity research. Its well-characterized receptor profile, high purity, and clear physicochemical parameters make it indispensable for dopaminergic signaling and Parkinson’s disease studies. As APExBIO continues to refine its product portfolio, Rotigotine remains a reference compound for reproducible, high-impact neuroscience research. For comprehensive product specifications and ordering, see the official Rotigotine product page. For further mechanistic analysis, consult this strategic overview, which this dossier extends by providing up-to-date atomic evidence and explicit workflow recommendations.